The Prompt: FDA Plans To Use AI To Speed Up Scientific Review
Welcome back to The Prompt.
The FDA announced yesterday it had rolled out an agency-wide generative AI tool called Elsa to speed up scientific reviews and spot inspection targets.
AI is finding its way into the public sector and its latest entry point is the U.S. Food and Drug Administration, which announced yesterday that it had rolled out an agency-wide generative AI tool called Elsa. The FDA plans to use the AI system to locate high-priority inspection targets, generate code to create databases and summarize information for safety assessments and scientific reviews.
Now let's get into the headlines.
Meta, which generates 97% of its revenue by advertising on Facebook and Instagram, is developing AI tools that aim to help brands fully create and target ads, according to the Wall Street Journal. It's also planning to use AI to personalize ads by tweaking them for different users based on factors like location and budget.
Chip giant Nvidia reported $44.1 billion in revenue for its latest quarter ending April 27, beating Wall Street forecasts. But the company's year over year earnings are ebbing, Forbes reported, in part thanks to an almost $50 billion hit after the Trump administration stopped it from exporting its H20 AI chips to China.
Academic journals and scientific websites are being swamped by bots scraping hundreds of millions of documents and photographs to train generative AI models, according to Nature. The aggressive bot scraping activity has pushed some sites to the brink of closing their doors, both by skyrocketing costs thanks to overloading servers and slowing down site functions for legitimate users.
Alex Ratner, CEO of Snorkel AI, remembers a time when data labeling —the grueling task of adding context to swathes of raw data and grading an AI model's response— was considered 'janitorial' work among AI researchers. But that quickly changed when ChatGPT stunned the world in 2022 and breathed new life (and billions of dollars) into a string of startups rushing to supply human-labeled data to the likes of OpenAI and Anthropic to train capable models.
Now, the crowded field of data labelling appears to be undergoing another shift. Fewer companies are training large language models from scratch, leaving that task instead to the tech giants. Instead, they are fine-tuning models and building applications in areas like software development, healthcare and finance, creating demand for specialized data. AI chatbots no longer just write essays and haikus; they're being tasked with high stakes jobs like helping physicians make diagnoses or screening loan applications, and they're making more mistakes. Assessing a model's performance has become crucial for businesses to trust and ultimately adopt AI, Ratner said. 'Evaluation has become the new entry point,' he told Forbes.
That urgency for measuring AI's abilities across very specific use cases has sparked a new direction for Snorkel AI, which is shifting gears to help enterprises create evaluation systems and datasets to test their AI models and adjust them accordingly. Data scientists and subject matter experts within an enterprise use Snorkel's software to curate and generate thousands of prompt and response pairs as examples of what a correct answer looks like to a query. The AI model is then evaluated according to that dataset, and trained on it to improve overall quality.
The company has now raised $100 million in a Series D funding round led by New York-based VC firm Addition at a $1.3 billion valuation— a 30% increase from its $1 billion valuation in 2021. The relatively small change in valuation could be a sign that the company hasn't grown as investors expected, but Ratner said it's a result of a 'healthy correction in the broader market.' Snorkel AI declined to disclose revenue.
Read the full story on Forbes.
In what may have been among the most expensive acquisition announcements, OpenAI spent nearly $3 million to produce a 9-minute video of CEO Sam Altman and LoveFrom founder Jony Ive walking through the streets of San Francisco and discussing their ambitions to create a new device for interacting with ChatGPT, according to the San Francisco Standard. The AI model maker hired Oscar winning director Davis Guggenheim to film the video and obtained permits to shut down roadways in the city. The video was part of OpenAI's splashy announcement of its acquisition of Ive's hardware startup io in a $6.5 billion all-stock deal.
Chatbots are sucking up to their users (even if that means giving them harmful advice) in order to keep them hooked on the technology, according to a new study, The Washington Post reported. In one scenario, an AI chatbot suggested a fictional recovering drug addict 'take a small hit of meth,' to stay focused. Tech giants and top AI companies like OpenAI, Meta and Google have recently released updates to make their AI models more personalized— learning more about the user from their chat history and internet activity and serving up content that best aligns with their preferences–in order to make it less tempting to start using a competitor's product.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
39 minutes ago
- Forbes
Rise Of The Machines: A Dividend Revolution Yielding Up To 9.7%
Army of robots. 3D illustration Big companies are about to make even more money. They have discovered they no longer need armies of new hires to grow—extremely bullish news for shareholders because human employees are expensive. Good ones can also be notoriously elusive. For example, I'm the longest-standing member of my kids' school marketing committee, and we're always scrambling for volunteers (what non-profit isn't?). Until now, that is. Over the weekend, we welcomed the most talented marketer I've ever worked with to our team: ChatGPT 4.5. 'GPT' graciously accepted our volunteer position, and we're already actively boosting online referrals for the school. I'm learning cutting-edge 'AI referral' techniques straight from the entity that invented them. It was the easiest recruitment effort I've ever experienced. GPT and I were already collaborating closely to market and sell several software products, so extending our teamwork to the non-profit world was seamless. The same dynamic is quietly playing out at for–profit companies, particularly the tech giants that dominate the cap-weighted S&P 500. A senior executive friend at Meta (META) recently confirmed to me that the company has essentially frozen hiring, pivoting entirely toward AI-driven growth. It already shows in the numbers. Over the past year Meta has increased revenues by 22% while only hiring 10% more people. Sales are growing faster than humans, a trend that I expect to accelerate in the months and years ahead. In fact, I wouldn't be surprised if Meta has already reached peak headcount—which means profits are set to surge even more. And Meta isn't alone in this 'growing without hiring' trend. Alphabet (GOOG) grew revenues by 14% without any net new hires. And Nvidia (NVDA) did grow headcount by 13%, but for good reason—sales exploded by 126%! Microsoft (MSFT) is likewise sailing along without the need for new engineers, with 16% revenue growth on just a 3% headcount increase: Tech Growth The AI adoption at these companies is just beginning. These profit machines are already selling $1 to $2 million in product per employee, but their profits are going to pop as they sell even more without the expense drag of adding new employees! This four-pack packs 20% of the S&P 500 index. When we combine Amazon (AMZN), Tesla (TSLA), Netflix (NFLX) and Apple (AAPL)—four more tech companies that are scaling without hiring—we have 32% of the index. Earlier in the year, I warned that the 'tech heaviness' of the S&P 500 was dangerous—and it sure was during the tariff troubles of March and April. But with trade tensions fading and tech profits exploding thanks to lean payrolls, these big 8 companies are now set to power the index higher. Plus, we have a weakening US dollar. Stocks are, of course, priced in dollars. So, a softer dollar is another bullish catalyst for the S&P 500. As income investors, we can tap this rising tide for steady income. To do so, we'll use covered calls—a strategy where we buy stocks and then sell ('write') call options to other investors. We earn income now from the option premiums we collect, paid upfront to agree to sell our shares at a higher price later. Market volatility from a tumultuous spring means these options pay generous premiums right now (covered call options pay more when things are bouncing around!). So, this is a good market moment to cash in on leftover fear. I'm talking about dividends up to 9.7% that will benefit from the S&P 500 soaring towards 9000. (Yes, it sounds wild—but with record profits plus a declining dollar, this is a potential price target before the end of Trump 2.0.) Eaton Vance Tax-Managed Global Diversified Equity Income Fund (EXG) yields 9.2% and trades at a 6% discount. That's a sweet deal because it holds big winners like Amazon, Alphabet, and Microsoft, then boosts income by selling covered calls on the S&P 500 and international indices. The income from these constantly expiring calls is the key to the EXG's sky-high 'synthetic yield.' The fund collects premiums from option buyers immediately after it writes these calls, generating steady income for shareholders. We can think of this as 'renting' out positions to generate extra cash. EXG owns the underlying shares behind the S&P 500. Each month it leases its collection of stocks and collects the option premiums. Rinse and repeat. Nuveen S&P 500 Buy-Write Income Fund (BXMX) pays 8.1% and trades at a 9% discount to its net asset value (NAV)—another good deal because we're talking Apple and Amazon for 91 cents on the dollar. Finally the Global X S&P 500 Covered Call ETF (XYLD) dishes a 9.7% dividend. It is an ETF, so it trades at par ('fair value'), as most do. XYLD owns the S&P 500 stocks and has also written calls on the S&P 500 that expire later in June. When that happens, the fund will write new calls for July—delivering more tasty income to its investors. Covered Call Funds As sellers of covered calls, they exult in market volatility that delivers high option premiums. Plus, their NAVs have a tailwind—tech profits popping! Brett Owens is Chief Investment Strategist for Contrarian Outlook. For more great income ideas, get your free copy his latest special report: How to Live off Huge Monthly Dividends (up to 8.7%) — Practically Forever. Disclosure: none
Yahoo
44 minutes ago
- Yahoo
Nvidia Retains Top Pick as AI Momentum Grows
Nvidia (NASDAQ:NVDA) remains a top sector pick after Bank of America's Vivek Arya returned from investor events in San Francisco with very positive feedback on AI demand, reaffirming his Buy rating and maintaining a $180 price target. Arya noted that Nvidia's Blackwell rack-scale systems now account for about 70% of compute sales, with Blackwell Ultra production slated to begin in Q2 alongside Rubin and Feynman on track, underscoring seamless generational transitions and limited ramp costs. Warning! GuruFocus has detected 4 Warning Signs with NVDA. He highlighted that the recent lifting of AI Diffusion export rules opens a sovereign AI growth vectorsovereign governments and CSPs are expected to build their own foundational models, expanding Nvidia's addressable market beyond hyperscalers. Addressing China-related risks, Arya emphasized that Nvidia considers its China AI exposure fully de-risked after H20 export restrictions, meaning any future sales into the $50 billion China AI TAM would be incremental upside, as current data center forecasts exclude China revenues. Management's guidance around Blackwell execution and the de-risked China outlook alleviates investor concerns that had restrained the stock over the past year. With the GB200 NVL systems fully ramping and strong cloud and enterprise interest, Nvidia's positioning in the ongoing AI wave appears reinforced even as macro uncertainties persist. Investors should care because these developments validate Nvidia's roadmap and could drive upside to consensus estimates, especially if sovereign commitments and China re-entry accelerate. Also, from the chart we can see that consensus estimates point to over a 20% bump from its current price. In fact, the GF value is at $273, which is an enormous upside from current levels. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
FDA deploys generative AI tool Elsa to transform agency operations in historic move
In a major step toward modernizing its operations, the U.S. Food and Drug Administration (FDA) on Monday launched Elsa, a generative artificial intelligence (AI) tool, designed to help agency employees, including scientific reviewers and field investigators, work smarter and faster. Elsa is the regulator's first large-scale foray into generative AI and is being dubbed as a turning point for the agency. Built in a secure GovCloud environment, the tool gives staff the ability to quickly search and summarize internal documents without compromising sensitive research and data handled by FDA staff. More than a chatbot, the tool also allows FDA scientists and subject-matter experts to spend less time on tedious, repetitive tasks that often slow down the review the AI models do not train on information submitted by regulated industries, ensuring the confidentiality of proprietary research. 'Today marks the dawn of the AI era at the FDA with the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee,' the agency's Chief AI Officer, Jeremy Walsh, said. 'As we learn how employees are using the tool, our development team will be able to add capabilities and grow with the needs of employees and the agency.' The agency said it is already using the tool to speed up clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets. FDA Commissioner Dr. Marty Makary said the launch came ahead of schedule and under budget due to strong collaboration among internal teams. 'Following a very successful pilot program with FDA's scientific reviewers, I set an aggressive timeline to scale AI agency-wide by June 30,' he said. 'Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers.' Elsa is a large language model–powered AI tool designed to assist with reading, writing, and summarizing. It can summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications. It is seen as the first step in a broader strategy to embed AI into FDA workflows. 'Prioritizing efficiency and responsibility, the FDA launched Elsa ahead of schedule using an all-center approach. Leaders and technologists across the agency collaborated, demonstrating the FDA's ability to transform its operations through AI,' the agency within the U.S. Department of Health and Human Services said in a release. As employees use the tool, its developers plan to expand capabilities to meet emerging needs. This includes improving usability, data processing, generative-AI functions, and tailoring outputs to center-specific needs while maintaining strict information security and compliance with FDA policy. The agency-wide rollout was coordinated by Walsh, the agency's newly-appointed Chief AI Officer, and Sridhar Mantha. Walsh previously led enterprise-scale technology deployments across federal health and intelligence agencies, and Mantha recently led the Office of Business Informatics in CDER.
